Healthcare

Abiomed makes mechanical circulatory support devices used in cardiogenic shock and high-risk coronary procedures. Johnson & Johnson's fiscal 2025 Form 10-K places it in the MedTech cardiovascular portfolio.

• Controlling stakeJohnson & Johnson

ACUVUE is a contact-lens brand. Johnson & Johnson's fiscal 2025 Form 10-K says the MedTech Vision portfolio markets contact lenses under ACUVUE.

• Controlling stakeJohnson & Johnson

An adult-incontinence brand in Procter & Gamble's Baby, Feminine & Family Care segment.

• Controlling stakeProcter & Gamble

CAPLYTA is a treatment for schizophrenia and for depressive episodes associated with bipolar disorder and major depressive disorder. Johnson & Johnson's fiscal 2025 Form 10-K says it was acquired with Intra-Cellular Therapies on April 2, 2025.

• Controlling stakeJohnson & Johnson

CareCentrix is a health-services company named in the Walgreens acquisition release.

• Portfolio investmentSycamore Partners

CARVYKTI is a CAR-T therapy for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and says it is licensed and developed in collaboration with Legend Biotech.

• Controlling stakeJohnson & Johnson

Cellview Imaging is a retinal-imaging company EssilorLuxottica describes in its 2025 universal registration document.

• Controlling stakeEssilorLuxottica

Clorox Healthcare is a professional brand the Clorox 10-K says the company markets.

• Controlling stakeThe Clorox Company

CONCERTA is an extended-release treatment for attention deficit hyperactivity disorder. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

An oral-care brand in Procter & Gamble's Health Care segment, covering toothpastes and related products.

• Controlling stakeProcter & Gamble

DARZALEX is a treatment for multiple myeloma, also sold as DARZALEX FASPRO. Johnson & Johnson's fiscal 2025 Form 10-K says Genmab owns related patent families and Janssen Biotech, a wholly owned subsidiary, has an exclusive license. The royalty rate is 12% to 20% of DARZALEX net sales.

• Controlling stakeJohnson & Johnson

EDURANT is an antiretroviral medicine for HIV, used with other antiretroviral products. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

ERLEADA is an androgen receptor inhibitor for prostate cancer. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

Espansione is an ophthalmic-device company EssilorLuxottica describes in its 2025 universal registration document.

• Controlling stakeEssilorLuxottica

Essilor Instruments is an eye-health platform EssilorLuxottica names in its 2025 universal registration document.

• Controlling stakeEssilorLuxottica

EyeMed Vision Care is a managed vision-care business EssilorLuxottica names in its 2025 universal registration document.

• Controlling stakeEssilorLuxottica

Heidelberg Engineering is an eye-health platform EssilorLuxottica names in its 2025 universal registration document.

• Controlling stakeEssilorLuxottica

IMBRUVICA is a treatment for certain B-cell malignancies and chronic graft-versus-host disease. Johnson & Johnson's fiscal 2025 Form 10-K says it is developed in collaboration and co-marketed in the United States with Pharmacyclics LLC, an AbbVie company.

• Controlling stakeJohnson & Johnson

INVEGA SUSTENNA, also sold as XEPLION, and the longer-acting INVEGA TRINZA and TREVICTA, are treatments for schizophrenia. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.

• Controlling stakeJohnson & Johnson

Iris is an eye-hospital name EssilorLuxottica includes with its European clinics in the 2025 universal registration document.

• Controlling stakeEssilorLuxottica